New York City Metropolitan Area
I am an executive commercial and pipeline strategy leader with a passion for launching and growing brands that will help improve the lives of patients. I have built a track record of translating deep customer insights and clinical differentiation into winning commercial strategies from early stage compound evaluation through launch execution and in-line brand growth. Demonstrated success across global and US marketing, new product and business development, patient experience, and portfolio strategy spanning neuroscience, rare disease, immunology and metabolics. Dynamic and motivational leader with a focus on developing and inspiring high-performing teams, building external relationships, and fostering internal collaboration and followership across regional and functional areas.
Ownership of US new product strategy and business development for Johnson & Johnson's Neuroscience portfolio, tackling some of the most complex and and consequential challenges in brain health including major depressive disorder, schizophrenia, Alzheimer's disease, autism and Parkinson's Disease. Leading a senior team to shape compound strategies, provide aligned US input to clinical development plans and stage-gate decisions, and drive new product launch readiness to create short and long-term portfolio value. Additionally, I lead the commercial evaluation of US business development opportunities and the development of US launch readiness plans, including preliminary positioning, differentiation, value proposition and and novel go-to-market models.
Led the end-to-end patient experience strategy for Johnson & Johnson's pulmonary arterial hypertension portfolio, addressing the unique needs of individuals living with this rare and life-threatening disease. Accountable for the full spectrum of direct-to-consumer (DTC) marketing initiatives, encompassing impactful disease education and strategic brand awareness/activation campaigns. Spearheaded the development and implementation of comprehensive patient support programs focused on fulfillment and medication adherence. Additionally, I led the national field reimbursement team, providing essential in-office support to Cardiology and Pulmonology practices to optimize patient access and facilitate seamless medication onboarding.
Full P&L ownership for US commercialization and launch of Janssen’s 1st product launch in Multiple Sclerosis.